Previous 10 | Next 10 |
2023-08-08 09:00:00 ET Monday was a dark day for Sage Therapeutics (NASDAQ: SAGE) , a company that focuses on developing therapies for brain disorders. The stock plummeted by more than 53% after the company revealed that its blockbuster drug candidate, zuranolone, failed to win ...
2023-08-07 18:15:31 ET RBC Capital lowered its rating on Sage Therapeutics to sector perform on Monday, calling the FDA's decision not to approve zuranolone for major depressive disorder, or MDD, a "major setback" for the company. RBC said that while it believes the shares already refle...
2023-08-07 17:44:22 ET Summary On July 20, Johnson & Johnson, the mastodon of the healthcare sector, released its financial results for the 2nd quarter of 2023. However, those results were overshadowed by a federal judge's decision to dismiss a JNJ subsidiary's bankruptcy fili...
2023-08-07 17:39:56 ET Wedbush has downgraded Sage Therapeutics ( NASDAQ: SAGE ) to neutral following the FDA's decision to approve its drug zuranolone for the treatment of post-partum depression but not major depressive disorder, or MDD. The investment bank said it hadn't antic...
2023-08-07 10:04:18 ET Summary Sage Therapeutics, specializing in brain health, faces mixed financials with a decline in cash and an increase in expenses but anticipates revenue growth. Despite FDA approval for Zurzuvae (zuranolone) in PPD treatment, label warnings and controlled ...
2023-08-06 04:08:12 ET Summary DiaMedica Therapeutics is a clinical-stage biopharmaceutical company focused on developing recombinant proteins to treat life-threatening diseases. Its main clinical candidate, DM199, is undergoing evaluation in a Phase 2/3 study for the treatment of...
Postpartum depression (PPD) approval based on results from two Phase 3 clinical trials; in the SKYLARK Study treatment with ZURZUVAE rapidly improved symptoms of PPD at Day 15 and as early as Day 3 with sustained effect to Day 45 Mental health conditions are the leading cause of maternal mort...
Postpartum depression (PPD) approval based on results from two Phase 3 clinical trials; in the SKYLARK Study treatment with ZURZUVAE rapidly improved symptoms of PPD at Day 15 and as early as Day 3 with sustained effect to Day 45 Mental health conditions are the leading cause of maternal mo...
2023-08-03 07:40:27 ET BofA Securities is making more than 20 additions to its quantamental Alpha Surprise Portfolio, which continues to trail the market. The portfolio's return was +2.4% for July, trailing the S&P 500 ( SP500 ) ( SPY ) ( IVV ) ( VOO ) +3.1% ...
2023-08-02 08:23:00 ET Summary We’ve seen a shift in analyst sentiment over the last two weeks when looking at data in This Week in Earnings and STOXX 600 Earnings Outlook report. For the S&P 500, the week ending July 28th saw a total of 2,444 FY1 EPS revisions over a 7...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases ...
TOKYO and CAMBRIDGE, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today tha...
NEW YORK, NY / ACCESSWIRE / June 12, 2024 / Leading law firm Bleichmar Fonti & Auld LLP announces the upcoming July 22, 2024, deadline in the Biogen Inc. (Nasdaq:BIIB) Securities Class Action Lawsuit. If you invested in Biogen, you are encouraged to obtain additional information by visiting ...